Your session is about to expire
← Back to Search
BP1002 for Lymphoma
Study Summary
This trial is testing a new drug for patients with advanced lymphoma who have relapsed or are resistant to treatment. Up to 12 patients will be given the drug and monitored for safety and effectiveness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.You have a current infection of hepatitis B, hepatitis C, or HIV.I cannot become pregnant, am surgically sterile, postmenopausal, or use reliable birth control.I can take care of myself and am up and about more than half of my waking hours.My lymphoma came back or didn't fully respond to treatment.I do not have any untreated or uncontrolled infections.You are expected to live for at least 3 more months.I do not need therapy in my spinal fluid for brain involvement of my cancer.I've tried or can't use standard treatments, including stem cell transplant and CAR T-cell therapy.I am not pregnant, breastfeeding, nor plan to become pregnant or breastfeed during the study.I have recovered from previous cancer treatments, except for hair loss.I haven't had treatment for cancer, except for non-melanoma skin cancer, in the last year.I agree to use birth control during the study.I am able and willing to follow study instructions and communicate with the research team.My liver and kidney tests are within normal ranges.I haven't received any cancer treatment in the last 14 days.I am eligible for high dose chemotherapy and a stem cell transplant using my own cells.I have a slow-growing type of non-Hodgkin lymphoma.I am at high risk for TLS due to a large tumor or high lymphocyte count.I have not had a heart attack, stroke, or similar event in the last 6 months.I have seizures that are not controlled by medication.I have a diagnosis of a specific type of lymphoma or leukemia.
- Group 1: BP1002 monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the participant capacity of this trial?
"Affirmative. The information hosted on clinicaltrials.gov divulges that this medical trial, which was initially posted on November 5th 2020, is actively looking for candidates. To date, 30 people need to be enrolled across 1 centre."
What are the intended outcomes of this clinical investigation?
"As detailed by Bio-Path Holdings, Inc., the main outcome of this trial to be assessed within a 30 day period is discovering the Recommended Phase 2 dose (RP2D) of BP1002. Additionally, secondary research objectives involve determining Time to Progression (TTP), examining tumor response via bone marrow aspirate and Complete Blood Counts (CBC) with appropriate uniform criteria as defined by Response Evaluation Criteria in Lymphoma (RECIL) 2017, CLL guidelines, and International Workshop on Waldenström's Macroglobulinemia (IWWM 6th)."
Could you provide information regarding the current enrollment status of this research?
"Indeed, information available on clinicaltrials.gov affirms that this medical trial is actively recruiting patients. Initially posted on November 5th 2020 and most recently updated 18th of the same month; 30 individuals need to be accepted from a single site."
Is there an official sanctioning of L-Bcl-2 antisense oligonucleotide by the Food and Drug Administration?
"Due to the limited amount of data concerning safety and efficacy, our team at Power gave L-Bcl-2 antisense oligonucleotide an estimation score of 1."
Share this study with friends
Copy Link
Messenger